|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| «12...910111213141516171819...4142» |
- Enrollment change, Trial termination, Trial primary completion date, Metastases: AHN-12 Biodistribution in Advanced Leukemia (clinicaltrials.gov) - May 19, 2015
P1, N=8, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=30 --> 8 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jul 2014; Slow accrual
- | clofarabine / Generic mfg.
Trial completion, Trial primary completion date: Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. (clinicaltrials.gov) - May 19, 2015
P1, N=36, Completed, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=30 --> 8 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jul 2014; Slow accrual Suspended --> Completed | Trial primary completion date: Jan 2013 --> Dec 2014
- Trial completion, Enrollment change: alloCIK: Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (clinicaltrials.gov) - May 19, 2015
P2, N=24, Completed, Sponsor: Singapore General Hospital
Suspended --> Completed | Trial primary completion date: Jan 2013 --> Dec 2014 Recruiting --> Completed | N=20 --> 24
- Enrollment change, Post-transplantation: T-Cell Depleted Double UCB for Refractory AML (clinicaltrials.gov) - May 16, 2015
P2, N=3, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | N=20 --> 24 N=24 --> 3
- | Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion, Trial primary completion date: Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia (clinicaltrials.gov) - May 13, 2015
P3, N=161, Completed, Sponsor: Universit
N=24 --> 3 Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Feb 2014
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment open: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - May 12, 2015
P2, N=6, Recruiting, Sponsor: Celator Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Feb 2014 Not yet recruiting --> Recruiting
- Biomarker, Enrollment closed: Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2015
P=N/A, N=9, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Combination therapy: A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (clinicaltrials.gov) - May 12, 2015
P1, N=44, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Active, not recruiting Recruiting --> Completed | N=116 --> 44
- | Biomarker, Trial completion: Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 12, 2015
P=N/A, N=40, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | N=116 --> 44 Active, not recruiting --> Completed
- Elitek (rasburicase) / Sanofi
Trial completion: Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - May 12, 2015
P=N/A, N=25, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Biomarker, Trial primary completion date: Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 8, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Trial primary completion date: Jul 2010 --> Jan 2100
- || Trial primary completion date: Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 8, 2015
P=N/A, N=2500, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jul 2010 --> Jan 2100 Trial primary completion date: Jan 2010 --> Jan 2100
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Phase classification: Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 8, 2015
P1, N=15, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2010 --> Jan 2100 Phase classification: P1/2 --> P1
- || Trial primary completion date: Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
Phase classification: P1/2 --> P1 Trial primary completion date: Oct 2010 --> Jan 2100
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Trial primary completion date: Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin (clinicaltrials.gov) - May 7, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2010 --> Jan 2100 Trial primary completion date: Dec 2011 --> Jan 2100
- Biomarker, Enrollment open, Trial primary completion date, IO biomarker: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2011 --> Jan 2100 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100
- Biomarker, Trial completion: Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100 Active, not recruiting --> Completed
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Enrollment change, Combination therapy: Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 7, 2015
P1/2, N=50, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=19 --> 50
- Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - May 6, 2015
P=N/A, N=15, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed | N=19 --> 50 Trial primary completion date: Apr 2015 --> Apr 2016
- || Biomarker, Trial primary completion date: Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Feb 2011 --> Jan 2100
- || Biomarker, Trial primary completion date: Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=75, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Feb 2011 --> Jan 2100 Trial primary completion date: Jan 2021 --> Jan 2100
- || Biomarker, Trial initiation date, Trial primary completion date: Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=149, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2021 --> Jan 2100 Initiation date: Sep 2009 --> Feb 2013 | Trial primary completion date: Jun 2011 --> Jan 2100
- ||| Enrollment open, Trial primary completion date: Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=100, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Sep 2009 --> Feb 2013 | Trial primary completion date: Jun 2011 --> Jan 2100 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100
- Biomarker, Enrollment closed: Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2012 --> Jan 2100 Completed --> Active, not recruiting
- | Biomarker, Trial completion, Trial initiation date: Biomarkers in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2015
P=N/A, N=18, Completed, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Sep 2009 --> Feb 2009
- || Biomarker, Trial primary completion date: Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 (clinicaltrials.gov) - May 5, 2015
P=N/A, N=90, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: Sep 2009 --> Feb 2009 Trial primary completion date: Jan 2011 --> Jan 2100
- | Trial completion, Enrollment change: Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=15, Completed, Sponsor: PX Biosolutions
Trial primary completion date: Jan 2011 --> Jan 2100 Enrolling by invitation --> Completed | N=30 --> 15
- Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial primary completion date, Combination therapy: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 29, 2015
P2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)
Enrolling by invitation --> Completed | N=30 --> 15 Trial primary completion date: May 2015 --> May 2016
- | LMB-2 / National Cancer Institute
Trial completion: LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma (clinicaltrials.gov) - Apr 28, 2015
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- || Xpovio (selinexor) / Karyopharm
Trial initiation date, Combination therapy: Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2015
P1, N=60, Not yet recruiting, Sponsor: Bhavana Bhatnagar
Recruiting --> Completed Initiation date: Mar 2015 --> Jun 2015
- | arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2015 --> Jun 2015 No longer recruiting --> Completed
- | LMB-2 / National Cancer Institute
Trial completion: Immunotoxin in Treating Patients With Leukemia or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Not yet recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Apr 25, 2015
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- azacitidine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Apr 25, 2015
P1, N=14, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=21 --> 14 | Trial primary completion date: Apr 2015 --> Mar 2014
- cytarabine / Generic mfg.
Trial primary completion date: A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Apr 23, 2015
P3, N=500, Active, not recruiting, Sponsor: Northern Italy Leukemia Group
Active, not recruiting --> Completed | N=21 --> 14 | Trial primary completion date: Apr 2015 --> Mar 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- uproleselan sodium (APL-106) / GlycoMimetics
Enrollment open, Combination therapy: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML (clinicaltrials.gov) - Apr 23, 2015
P1/2, N=77, Recruiting, Sponsor: GlycoMimetics Incorporated
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy: Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML (clinicaltrials.gov) - Apr 22, 2015
P1, N=12, Terminated, Sponsor: New York Medical College
Active, not recruiting --> Recruiting N=16 --> 12
- Rydapt (midostaurin) / Novartis
Trial primary completion date: Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 21, 2015
P1, N=21, Active, not recruiting, Sponsor: Alison Walker
N=16 --> 12 Trial primary completion date: Dec 2014 --> Apr 2014
- Vesanoid (tretinoin) / Roche
Trial primary completion date: Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 19, 2015
P1, N=24, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2014 --> Apr 2014 Trial primary completion date: Jan 2015 --> Jan 2016
- uproleselan sodium (APL-106) / GlycoMimetics
Enrollment closed, Trial initiation date, Combination therapy: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML (clinicaltrials.gov) - Apr 17, 2015
P1/2, N=77, Active, not recruiting, Sponsor: GlycoMimetics Incorporated
Trial primary completion date: Jan 2015 --> Jan 2016 Not yet recruiting --> Active, not recruiting | Initiation date: Dec 2014 --> Mar 2015
- IGN523 / Igenica Biotherapeutics
Enrollment closed, Enrollment change, Trial primary completion date: A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML (clinicaltrials.gov) - Apr 16, 2015
P1, N=19, Active, not recruiting, Sponsor: Igenica Biotherapeutics, Inc.
Not yet recruiting --> Active, not recruiting | Initiation date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Sep 2015 --> Jun 2015
- | tigecycline / Generic mfg.
Trial completion, Trial primary completion date: Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 15, 2015
P1, N=27, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Sep 2015 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2014
- Trial primary completion date: Lenalidomide Plus Chemotherapy for AML (clinicaltrials.gov) - Apr 14, 2015
P1, N=28, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- atorvastatin / Generic mfg.
Trial primary completion date: Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 14, 2015
P2, N=41, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- | Trial termination, Trial primary completion date: RICMAC: Dose-reduced Versus Standard Conditioning in MDS/sAML (clinicaltrials.gov) - Apr 14, 2015
P3, N=129, Terminated, Sponsor: European Group for Blood and Marrow Transplantation
Trial primary completion date: Dec 2014 --> Dec 2016 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Jan 2015
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment change: Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 14, 2015
P1, N=16, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Jan 2015 N=28 --> 16
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 14, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=28 --> 16 Trial primary completion date: Mar 2015 --> Sep 2015
- || lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial primary completion date: 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=88, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Synribo (omacetaxine mepesuccinate) / Teva
Trial initiation date, Trial primary completion date: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Apr 14, 2015
P2, N=66, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Dec 2014 --> Aug 2015 | Trial primary completion date: Dec 2017 --> Aug 2018